Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks. That's indeed a big vote of confidence. Good DD.
FYI, per Propthink report co-authored by Aaifa C, pps is expected to be in double digits end of this year.
FWIW, there is a highly respected MD doctor Aaifa Choudhary who has written a blog on TSRX along with propthink team. She definitely knows what she is writing
Excellent. Can you elaborate on the 'Vote from big guys' Thanks
Starter position 10k at 1.06 today. Thanks, $heff
Hepatocelluar Carcinoma (HCC) aka liver cancer usually predicated by Heptatis B infection largely prevalant in asian countries including China.
Not that I doubt the statment in the CTIX PR release but mainly for me to better understand the reasoning behaind the combo therapy when sunitinib alone is shown to shrink RCC tumors.
Again from this article: http://www.news-medical.net/health/Renal-Cell-Carcinoma-Treatments.aspx
The benefit for sunitinib was significant across all major patient subgroups, including those with a poor prognosis at baseline. 28% of sunitinib patients had significant tumor shrinkage compared with only 5% of patients who received interferon-a.
Maybe I am missing something here..
Good move today. Where do you see TSRX pps upon their results due next couple of months (March ?)
FDA allowed under SPA. Company got the approval to cut time & cost. HCC is a huge problem worldwide
Reminds me of a company called Nuvelo years ago that bombed in P3 trial of their anticoaglant based on snake venom after a huge hype similar to CLSN. Dew might remember that fiasco.
Nuvelo's CEO Dr. Love touted high confidence of trial success sucking in lot of retail investors who lost their shirt. Lawsuit followed and few got a penny on a dollar including me.
I see similar events unfolding with Celsion (there is a lawsuit news today).
Lesson: Never trust a CEO who is over confident...lol
I would appreciate if someone who is more knowledgable can respond.
I see from this article that Sunitinib alone has fairly strong efficacy and can significantly shrink tumors in RCC. Please
see:
http://www.news-medical.net/health/Renal-Cell-Carcinoma-Treatments.aspx
The recent PR from CTIX reflected a combo regimen with the same outcome (tumor shrinkage).
Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we’ve used in which actual tumor shrinkage is noted.”
How are the researchers and/or company attributing that Kevetrin has made a difference and that the observed shrinkage is not due to Sunitinib ? Is there a article to show that sunitinib is not effective in cell line 786 ?
Thanks
Is there a CT scan included within the treatment efficacy analysis ?..just curious on how they are approaching to determine whether tumors have stabilized or even begin to shrink. TIA
$NAVB..well said, Lol. the JP Morgan stake in NAVB has significantly de-risked the approval concerns. I bet they have done more than 'once over' the manufacturing issues per last CRL.
Shorts have started to feel the heat
Thanks. Yah..that was an ouch out there..luckily not a big one as I sensed something wrong few weeks and I believe I expressed my concerns too on the c_lsn board. Sad indeed for all the promises (false or otherwise) the managment made knowingly or unknowingly.
Better still, if it works in all of 50% of human beings who apparently carry that mutant P53 Gene, it will be in trillions..lol
You are correct. Kevetrin should be effective (if the mouse models are accurate predictors!) in about 50% of cancers.
Not me..lol. Whatever basis I took off from the table (thanks to you, Bioman ), I have already put to work few mins back on CTIX.
I am a new shareholder of CTIX now with initial position of 5k at 1.89. Like the crowd here.
$INSM ..Any idea on today's weakness in INSM..seems like a buying opportunity especially considering the automatic insider buy program the company's CEO has instituted. Thanks
Good DD. INO will be the stock to watch this year with so many catalysts. Their collaboration with PATH on Malaria vaccine alone is note worthy and will bump the PPS.
I am seeing $2 in couple of months.
I expect the news to be mixed. However I am darn sure Hisun will move forward signing the contract for sFDA approval of Thermodox in China. Too large an opportunity for them to ignore.
I am really glad we have such a huge market potential in China without being hamstrung by FDA rigor. No wonder patients see global treatments nowadays.
We should get a PR in another hr or so (anytime after 7 AM EST).
Just one caveat though..they still have on-going Dignity and Ablate trials for other indications. All hope is not lost if we come short tomorrow, just saying..but hope I am wrong.
Anyway I am pretty positive there will be another PR prior to CC. Probably between 7 and 7:30 AM EST
That exactly what ACAD did. So far CLSN is doing the exact drill as ACAD (time, CC notice one day earlier at 4 PMm use of Pivotal word etc). I bet they issue a PR with some results around 7:30 AM EST as well. See ACAD's sequence of events...
PR prior to CC tomorrow...here is why
I bet Celsion issues a PR probably 30 mins earlier (like ACAD) did to actually tell the world the TL results. Reason is for any hearing impaired shareholders, CC audio is not enough. And they have every right to know the results at the same time as anyone else.
Expect to see a PR prior to CC.
Kudos, TOB..great find. Thanks my friend
Amen !!
CLSN Halt !
I don't think you have any idea on the potential of Thermodox if results are +ve.
Please take my word..I am serious.
Tomorrow"s CC is confirmed at 7 AM CT
Conference Call tomorrow at 8 AM unconfirmed but very likely from reliable tweets
What tumbled ? Somone is smoking green but definitely not the right type at this scam website. PM actually is up by 22cents..lol
If anyone in Philly or closeby care to drop in at the CBI Luncheon would be wonderful Pretty sure, Frank being a Chair, won't cancel his trip.
P.S: If Frank is seen laughing and making jokes, we get the idea..lol
I don't see any presentaion or case studies by Celsion other than Frank heading the Chair. Lame stuff but why go as the agenda is all about branding/partnering/marketing an Oncology product
Chairperson: Frank Gibson Director of Product Development Celsion
is among the distinguished speakers
CLSN to participate in CBI Forum
News Breaks
January 30, 2013
05:55 EDT AVEO, AVEO, CAH, CAH, ABC, ABC, AET, AET, CVS, CVS, BMY, BMY, JPM, JPM, MCK, MCK, CLSN, CLSN CBI to host a forum
6th Annual Forum on Oncology Market Access & Payer Strategies is being held in Philadelphia on January 30-31.
Awesome. You bet I buy you a steak once the PR comes out...
I feel the report on HCC therapies by Decision Resources is a strong 'signal' for a +ve results.
Mark this post...No need to thank me, when the results come out
Good Press..the authors sound as if the TDOX success almost given
http://www.marketwatch.com/story/the-treatment-landscape-for-hepatocellular-carcinoma-will-change-dramatically-over-the-next-ten-years-due-to-the-launch-of-new-therapies-in-the-united-states-and-eu5-2013-01-29
Interesting titbits from Griffins report:
The major events depicted in the timeline are:
- Early December – HEAT trial ends with an announcement that at least 380 events have occurred.
- Jan-April 2013 – Marketing partners are enlisted in major regions (e.g., Europe and China)
- February 2013 – Celsion has a pre-NDA meeting with the FDA and EMA to discuss data submissions
- May/June 2013 – Celsion files the HEAT data with regulatory agencies (i.e., FDA, EMA, SFDA)
- Late 2013/early 2014 – Regulatory agencies approve ThermoDox
- Jan-April 2014 – ThermoDox is launched in major markets
I think managment sans the PR for the results is executing the plan pretty good. Feb will be a very busy month for Celsion assuming the results are good.
Guys, we are very close to the wire..hang on